An update on the safety of biologics for the treatment of psoriasis.

INTRODUCTION

Biologic therapies have changed the management of moderate-to-severe psoriasis by targeting key immunologic pathways. With increasing real-world use, long-term safety profiles are important for clinical decision-making.

AREAS COVERED: The objective of this research is to provide an update on the safety of biologics over the past five years in psoriasis, including infection risk, malignancy, immunogenicity, and long-term outcomes. An informal literature review through PubMed was done using key search terms from 2020 to 2025.

EXPERT OPINION: Biologic therapies are safe compared to older systemic drugs. Despite the minor risk for more common colds, which may be due to greater social interactions, the benefits far outweigh the risks. Biologics have facilitated improving psoriasis care, providing greater clearance with less risk of severe side effects.